Anja M Billing, Young Chul Kim, Søren Gullaksen, Benedikt Schrage, Janice Raabe, Arvid Hutzfeldt, Fatih Demir, Elina Kovalenko, Moritz Lassé, Aurelien Dugourd, Robin Fallegger, Birgit Klampe, Johannes Jaegers, Qing Li, Olha Kravtsova, Maria Crespo-Masip, Amelia Palermo, Robert A Fenton, Elion Hoxha, Stefan Blankenberg, Paulus Kirchhof, Tobias B Huber, Esben Laugesen, Tanja Zeller, Maria Chrysopolou, Julio Saez-Rodriguez, Christina Magnussen, Thomas Eschenhagen, Alexander Staruschenko, Gary Siuzdak, Per L Poulsen, Clarissa Schwab, Friederike Cuello, Volker Vallon, Markus M Rinschen
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood. METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia...
December 28, 2023: Circulation